LeMaitre Q3 2022 Financial Results

Rhea-AI Summary

LeMaitre (Nasdaq:LMAT) reported Q3 2022 results with sales of $39.0 million, a 2% increase year-over-year. Operating income fell 32% to $6.2 million with a margin of 16%. Net income decreased 16% to $5.5 million, with earnings per share at $0.25, down 17%. Sales growth was driven by carotid shunts (+23%) and other products. The company also announced a quarterly dividend of $0.125 per share, payable December 1, 2022. Guidance for Q4 2022 estimates sales of $39.8-$42.2 million and expects a gross margin of 65.8%. Cash and investments rose by $4.1 million to $79.7 million.

Positive

• Q3 2022 sales increased by 2% year-over-year, with 7% organic growth.
• Quarterly dividend of $0.125/share approved, enhancing shareholder returns.
• Cash and investments increased by $4.1 million to $79.7 million.
• Sales growth driven by carotid shunts (+23%) and other vascular products.

Negative

• Operating income decreased by 32% to $6.2 million.
• Net income fell 16% to $5.5 million.
• Gross margin decreased to 64.2% from 64.8% the previous year.

BURLINGTON, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2022 results, announced a $0.125/share quarterly dividend and provided guidance.

Q3 2022 Financial Results

• Sales of $39.0mm, +2% (+7% organic) vs. Q3 2021
• Op. income $6.2mm, -32%
• Op. margin of 16%
• Net income of $5.5mm, -16%
• Earnings per diluted share $0.25, -17%
• Cash and investments +$4.1mm to $79.7mm

Q3 2022 sales growth was driven by carotid shunts (+23%), Artegraft (+12%), allografts (+10%) and embolectomy catheters (+10%). By geography, organic sales increased 11% in APAC, 8% in EMEA and 6% in the Americas. The strong U.S. dollar reduced sales by $1.9mm.

The gross margin decreased to 64.2% in Q3 2022 (vs. 64.8% in Q3 2021). The strong dollar reduced the gross margin by 1.7% year-over-year. The Company had 213 direct labor employees as of September 30, up 54% year-over-year.

Q3 2022 operating income was $6.2mm. Q3 operating expense growth was driven by increased headcount, including a 28% larger salesforce (118 reps on September 30), as well as MDR-related regulatory expenses.

George LeMaitre, Chairman and CEO, said “In Q3 we grew 7% organically and increased our cash balance by $4.1 million to $79.7 million. We continue to build sales rep and direct labor headcount, both now at high-water marks. We expect these investments will drive organic sales growth and improvement to the gross margin in the quarters ahead.”

Business Outlook

		Q4 2022 Guidance	2022 Full Year Guidance
	Sales	$39.8mm - $42.2mm (Mid: $41.0mm, +4%, +9% Org.)	$160.5mm - $162.9mm (Mid:$161.7mm, +5%, +9% Org.)
	Gross Margin	65.8%	65.4%
	Op. Income	$6.6mm - $8.2mm (Mid: $7.4mm, -11%)	$26.5mm - $28.0mm (Mid $27.2mm, -25%)
	Op. Income Ex- Spec. Charge	-	$29.6mm - $31.1mm (Mid: $30.3mm, -17%)
	EPS	$0.24 - $0.29 (Mid: $0.26, -5%)	$0.91 - $0.97 (Mid: $0.94, -25%)
	EPS Ex- Spec. Charge	-	$1.02 - $1.08 (Mid: $1.05, -16%)

Quarterly Dividend

On October 25, 2022, the Company's Board of Directors approved a quarterly dividend of $0.125/share of common stock. The dividend will be paid on December 1, 2022 to shareholders of record on November 17, 2022.

Share Repurchase Program

On February 22, 2022, the Company's Board of Directors authorized the repurchase of up to $20.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 22, 2023, unless extended by the Board.

Board Appointment

On September 21, 2022, the Company’s Board of Directors appointed Martha Shadan as an independent director. Ms. Shadan has over 20 years of life sciences experience, including President and CEO at Miach Orthopedics and Rotation Medical. Ms. Shadan currently serves on the boards of CVRx and AdvaMed.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at http://www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company's website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

About LeMaitre

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

For more information about the Company, please visit http://www.lemaitre.com. 

Use of Non-GAAP Financial Measures

LeMaitre management believes that in order to better understand the Company's short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events as well as EBITDA or earnings before interest, taxes, depreciation and amortization and guidance for full year operating income and EPS excluding special charge. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, and the aforementioned non-GAAP profitability measures to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that evaluating EBITDA provides an approximation of the cash generating ability of its operations. The Company believes that the presentation of full year guidance for operating income and EPS excluding special charge provides an alternative and meaningful view of the Company’s profitability excluding the impact of the closure of the Company’s St. Etienne, France factory, a non-recurring event.

Forward-Looking Statements

The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, the status of our global regulatory approvals and compliance with regulatory requirements to market and sell our products both in the U.S. and outside of the U.S.; the duration and severity of the impact of COVID-19 on the global economy, our customers, our suppliers and our company; the risk of significant fluctuations in our quarterly and annual results due to numerous factors; the risk that assumptions about the market for the Company’s products and the productivity of the Company’s direct sales force and distributors may not be correct; the risk that we may not be able to maintain our recent levels of profitability; the risk that the Company may not realize the anticipated benefits of its strategic activities; risks related to the integration of acquisition targets; the acceleration or deceleration of product growth rates; risks related to product demand and market acceptance of the Company’s products and pricing; the risk that a recall of our products could result in significant costs or negative publicity; the risk that the Company is not successful in transitioning to a direct-selling model in new territories and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

CONTACT: 
J.J. Pellegrino, CFO, LeMaitre
781-425-1691
jjpellegrino@lemaitre.com

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands)
			September 30, 2022				December 31, 2021
			(unaudited)
Assets
Current assets:
	Cash and cash equivalents		$	16,913			$	13,855
	Short-term marketable securities			62,826				56,104
	Accounts receivable, net			20,094				19,631
	Inventory and other deferred costs			47,711				46,104
	Prepaid expenses and other current assets			4,842				4,189
	Asset held for sale			756				-
Total current assets				153,142				139,883
Property and equipment, net				15,351				17,059
Right-of-use leased assets				15,785				15,071
Goodwill				65,945				65,945
Other intangibles, net				48,063				52,710
Deferred tax assets				2,789				1,566
Other assets				973				568
Total assets			$	302,048			$	292,802
Liabilities and stockholders' equity
Current liabilities:
	Accounts payable		$	2,848			$	2,340
	Accrued expenses			17,400				16,332
	Acquisition-related obligations			1,363				1,271
	Lease liabilities - short-term			1,828				1,870
Total current liabilities				23,439				21,813
Lease liabilities - long-term				14,897				14,067
Deferred tax liabilities				60				70
Other long-term liabilities				2,405				2,701
Total liabilities				40,801				38,651
Stockholders' equity
	Common stock			236				235
	Additional paid-in capital			186,798				181,630
	Retained earnings			94,896				88,125
	Accumulated other comprehensive loss			(8,127	)			(3,435	)
	Treasury stock			(12,556	)			(12,404	)
Total stockholders' equity				261,247				254,151
Total liabilities and stockholders' equity			$	302,048			$	292,802

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(amounts in thousands, except per share amounts)
(unaudited)
		For the three months ended								For the nine months ended
		September 30, 2022				September 30, 2021				September 30, 2022				September 30, 2021
Net sales		$	39,028			$	38,368			$	120,697			$	114,921
Cost of sales			13,958				13,502				41,855				39,495
Gross profit			25,070				24,866				78,842				75,426
Operating expenses:
	Sales and marketing		8,229				6,941				24,321				20,210
	General and administrative		7,229				6,004				21,812				18,748
	Research and development		3,462				2,848				9,740				8,344
	Restructuring		-				-				3,107				-
Total operating expenses			18,920				15,793				58,980				47,302
Income from operations			6,150				9,073				19,862				28,124
Other income (expense), net
	Interest income		264				54				539				56
	Interest expense		-				(621	)			-				(1,693	)
	Foreign currency gain (loss)		(266	)			(72	)			(709	)			(105	)
Income before income taxes			6,148				8,434				19,692				26,382
Provision for income taxes			692				1,930				4,683				5,650
Net income		$	5,456			$	6,504			$	15,009			$	20,732
Earnings per share of common stock
	Basic	$	0.25			$	0.30			$	0.68			$	0.99
	Diluted	$	0.25			$	0.30			$	0.68			$	0.98
Weighted - average shares outstanding:
	Basic		21,984				21,592				21,959				20,920
	Diluted		22,217				21,935				22,149				21,251
Cash dividends declared per common share		$	0.125			$	0.110			$	0.375			$	0.330

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
SELECTED NET SALES INFORMATION
(amounts in thousands)
(unaudited)
		For the three months ended														For the nine months ended
		September 30, 2022							September 30, 2021							September 30, 2022							September 30, 2021
		$				%			$				%			$				%			$				%
Net Sales by Geography
	Americas	$	26,627			68	%		$	25,299			66	%		$	82,024			68	%		$	76,327			67	%
	Europe, Middle East and Africa		9,922			25	%			10,535			27	%			31,165			26	%			31,200			27	%
	Asia Pacific		2,479			7	%			2,534			7	%			7,508			6	%			7,394			6	%
Total Net Sales		$	39,028			100	%		$	38,368			100	%		$	120,697			100	%		$	114,921			100	%

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
Reconciliation between GAAP and Non-GAAP sales growth:
	For the three months ended September 30, 2022
		Net sales as reported		$	39,028
		Impact of currency exchange rate fluctuations			1,895
		Adjusted net sales					$	40,923
	For the three months ended September 30, 2021
		Net sales as reported		$	38,368
		Adjusted net sales					$	38,368
		Adjusted net sales increase for the three months ended September 30, 2022					$	2,555			7	%
APAC sales growth reconciliation between GAAP and Non-GAAP:
	For the three months ended September 30, 2022
		Net sales as reported		$	2,479
		Impact of currency exchange rate fluctuations			334
		APAC adjusted net sales					$	2,813
	For the three months ended September 30, 2021
		Net sales as reported		$	2,534
		Adjusted net sales					$	2,534
		APAC adjusted net sales increase for the three months ended September 30, 2022					$	279			11	%
EMEA sales growth reconciliation between GAAP and Non-GAAP:
	For the three months ended September 30, 2022
		Net sales as reported		$	9,922
		Impact of currency exchange rate fluctuations			1,486
		EMEA adjusted net sales					$	11,408
	For the three months ended September 30, 2021
		Net sales as reported		$	10,535
		Adjusted net sales					$	10,535
		EMEA adjusted net sales increase for the three months ended September 30, 2022					$	873			8	%
Americas sales growth reconciliation between GAAP and Non-GAAP:
	For the three months ended September 30, 2022
		Net sales as reported		$	26,627
		Impact of currency exchange rate fluctuations			74
		Americas adjusted net sales					$	26,701
	For the three months ended September 30, 2021
		Net sales as reported		$	25,299
		Adjusted net sales					$	25,299
		Americas adjusted net sales increase for the three months ended September 30, 2022					$	1,402			6	%
Reconciliation between GAAP and Non-GAAP projected sales growth:
	For the three months ending December 31, 2022
		Net sales per guidance (midpoint)		$	41,000
		Impact of currency exchange rate fluctuations			2,049
		Adjusted projected net sales					$	43,049
	For the three months ended December 31, 2021
		Net sales as reported		$	39,503
		Adjusted net sales					$	39,503
		Adjusted projected net sales increase for the three months ending December 31, 2022					$	3,546			9	%
Reconciliation between GAAP and Non-GAAP projected sales growth:
	For the year ending December 31, 2022
		Net sales per guidance (midpoint)		$	161,697
		Impact of currency exchange rate fluctuations			6,445
		Adjusted projected net sales					$	168,142
	For the year ended December 31, 2021
		Net sales as reported		$	154,424
		Adjusted net sales					$	154,424
		Adjusted projected net sales increase for the year ending December 31, 2022					$	13,718			9	%
Reconciliation between GAAP and Non-GAAP projected operating income:
	For the year ending December 31, 2022
		Operating income per guidance (midpoint)		$	27,242
		Impact of special charge			3,107
		Adjusted projected operating income					$	30,349
	For the year ended December 31, 2021
		Operating income as reported		$	36,425
		Adjusted operating income					$	36,425
		Adjusted projected operating income decrease for the year ending December 31, 2022					$	(6,076	)		-17	%
Reconciliation between GAAP and Non-GAAP projected EPS:
	For the year ending December 31, 2022
		EPS per guidance (midpoint)		$	0.94
		Impact of special charge		$	0.11
		Adjusted EPS					$	1.05
	For the year ended December 31, 2021
		EPS as reported		$	1.25
		Adjusted EPS					$	1.25
		Adjusted projected EPS decrease for the year ending December 31, 2022					$	(0.20	)		-16	%

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
		For the three months ended				For the nine months ended				LTM
		September 30, 2022				September 30, 2022				September 30, 2022
Reconciliation between GAAP and Non-GAAP EBITDA
	Net income as reported	$	5,456			$	15,009			$	21,184
	Interest (income) expense, net		(264	)			(539	)			(154	)
	Amortization and depreciation expense		2,328				7,145				9,504
	Provision for income taxes		692				4,683				6,413
	EBITDA	$	8,212			$	26,298			$	36,947

FAQ

What were LeMaitre's Q3 2022 earnings results?

LeMaitre reported Q3 2022 earnings of $5.5 million net income and earnings per share of $0.25.

What is the guidance for LeMaitre's Q4 2022?

LeMaitre expects Q4 2022 sales between $39.8 million and $42.2 million.

How did LeMaitre's sales perform in Q3 2022?

LeMaitre's sales for Q3 2022 were $39.0 million, representing a 2% increase year-over-year.

What factors contributed to LeMaitre's Q3 sales growth?

Growth was driven by carotid shunts (+23%), Artegraft (+12%), and other vascular products.

When will the quarterly dividend for LeMaitre be paid?

The quarterly dividend of $0.125 per share will be paid on December 1, 2022.